Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on October 2, 2015, covering events that occurred on October 1, 2015. The filing addresses Item 5.02 regarding the appointment of principal officers and their compensatory arrangements.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation terms.
Material Changes
The Board of Directors approved the following appointments effective October 1, 2015:
- Jeffrey Meckler: Appointed as Chief Executive Officer (CEO), transitioning from interim CEO.
- Annual Salary: $340,000.
- Annual Bonus: Up to 50% of base salary, subject to performance targets.
- Stock Options: Grant of 16,000,000 ten-year options vesting in five equal annual increments.
- Dr. Douglas Mayers: Appointed as Chief Medical Officer (CMO).
- Annual Salary: $280,000.
- Annual Bonus: Up to 35% of base salary, subject to performance targets.
- Stock Options: Grant of 2,400,000 ten-year options vesting in four equal annual increments.
Both employment agreements are on an at-will basis and include accelerated vesting provisions under certain conditions.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, outlook, management commentary on business strategy, or specific risk factors beyond the standard at-will employment terms.
Key Facts for Investor Verification
- Verify the total number of outstanding shares to assess the dilution impact of the 18.4 million new stock options granted.
- Confirm the specific performance targets required to achieve the executive bonuses.
- Review the accelerated vesting conditions detailed in the full employment agreements.
- Check subsequent filings for any changes to the interim status of other officers or the company's operational status.